$49.35
0.49[1.00%]
At close: Apr 25
$49.35
0[0.00%]
PreMarket: 5:49AM EDT
Bristol-Myers Squibb
(NYSE:BMY)Bristol-Myers Squibb Stock (NYSE:BMY), Analyst Ratings, Price Targets, Predictions
Bristol-Myers Squibb Co has a consensus price target of $56.28, established from looking at the 73 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Wells Fargo, and Redburn Atlantic on April 18, 2024, February 6, 2024, and February 6, 2024. With an average price target of $52.33 between Wells Fargo, Wells Fargo, and Redburn Atlantic, there's an implied 6.05% upside for Bristol-Myers Squibb Co from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Redburn Atlantic
B of A Securities
Cantor Fitzgerald
Deutsche Bank
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Bristol-Myers Squibb
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 5.37% | Wells Fargo | Mohit Bansal | $51 → $52 | Maintains | Equal-Weight | Get Alert |
| 02/06/2024 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 3.34% | Wells Fargo | Mohit Bansal | $58 → $51 | Maintains | Equal-Weight | Get Alert |
| 02/06/2024 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 9.42% | Redburn Atlantic | Steve Chesney | $77 → $54 | Downgrade | Buy → Neutral | Get Alert |
| 01/03/2024 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 21.58% | B of A Securities | Geoff Meacham | $68 → $60 | Downgrade | Buy → Neutral | Get Alert |
| 12/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 37.79% | B of A Securities | Geoff Meacham | $72 → $68 | Maintains | Buy | Get Alert |
| 11/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 11.45% | Cantor Fitzgerald | Olivia Brayer | $68 → $55 | Downgrade | Overweight → Neutral | Get Alert |
| 11/09/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 11.45% | Deutsche Bank | James Shin | → $55 | Initiates | → Hold | Get Alert |
| 11/02/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 9.42% | Daiwa Capital | Narumi Nakagiri | $68 → $54 | Downgrade | Outperform → Neutral | Get Alert |
| 10/30/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 39.82% | Goldman Sachs | Chris Shibutani | $81 → $69 | Maintains | Buy | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 1.32% | Morgan Stanley | Terence Flynn | $56 → $50 | Maintains | Underweight | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 3.34% | Barclays | Carter Gould | $60 → $51 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 21.58% | BMO Capital | Evan Seigerman | → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | — | William Blair | Matt Phipps | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 7.4% | HSBC | Rajesh Kumar | $55 → $53 | Upgrade | Reduce → Hold | Get Alert |
| 10/20/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 21.58% | UBS | Trung Huynh | $70 → $60 | Assumes | Neutral → Neutral | Get Alert |
| 10/11/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 13.48% | Morgan Stanley | Terence Flynn | $57 → $56 | Maintains | Underweight | Get Alert |
| 10/09/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 51.98% | Cantor Fitzgerald | Olivia Brayer | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 10/06/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 70.21% | Truist Securities | Robyn Karnauskas | → $84 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $49.35 | 70.21% | Truist Securities | Gregg Gilbert | → $84 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Bristol-Myers Squibb (BMY)?
The latest price target for Bristol-Myers Squibb (NYSE: BMY) was reported by Wells Fargo on April 18, 2024. The analyst firm set a price target for $52.00 expecting BMY to rise to within 12 months (a possible 5.37% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bristol-Myers Squibb (BMY)?
The latest analyst rating for Bristol-Myers Squibb (NYSE: BMY) was provided by Wells Fargo, and Bristol-Myers Squibb maintained their equal-weight rating.
When was the last upgrade for Bristol-Myers Squibb (BMY)?
The last upgrade for Bristol-Myers Squibb Co happened on October 27, 2023 when HSBC raised their price target to $53. HSBC previously had a reduce for Bristol-Myers Squibb Co.
When was the last downgrade for Bristol-Myers Squibb (BMY)?
The last downgrade for Bristol-Myers Squibb Co happened on February 6, 2024 when Redburn Atlantic changed their price target from $77 to $54 for Bristol-Myers Squibb Co.
When is the next analyst rating going to be posted or updated for Bristol-Myers Squibb (BMY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bristol-Myers Squibb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bristol-Myers Squibb was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Bristol-Myers Squibb (BMY) correct?
While ratings are subjective and will change, the latest Bristol-Myers Squibb (BMY) rating was a maintained with a price target of $51.00 to $52.00. The current price Bristol-Myers Squibb (BMY) is trading at is $49.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.